Corporation · excellence since 1987
Contact us
next‑gen medical innovation

Where biology & engineering converge

Minehart Medical advances precision diagnostics, robotic platforms, and bio‑integrated systems.

87 active patents
14 clinical trials
6 innovation hubs
Explore technology R&D overview
intelligent systems · real‑time analytics

Minehart Innovation Suite

Innovation architecture

Engineered from molecule to OR — four domains that define our pipeline.

Molecular
precision

CRISPR‑based assays, single‑cell proteomics, and real‑time mutation tracking.

Surgical
autonomy

AI‑guided robotics with haptic feedback and sub‑millimeter accuracy.

Neural
interface

Closed‑loop implants for neuromodulation and motor restoration.

Predictive
health

Federated learning models that anticipate critical events 48h earlier.

Breakthrough solutions

Currently in clinical validation and early adoption.
2025 – interventional

Minehart
Sphere‑9

  • 360° ablation + sensing
  • real‑time tissue distinction
  • FDA breakthrough designation
diagnostics

Patho‑Detect
HR

  • 12‑pathogen panel, 8 min
  • nanopore + machine vision
  • CLIA waiver pending
regenerative

Cyto‑Graft
Matrix

  • 3D bioprinted cartilage
  • vascularized construct
  • first‑in‑human 2024

R&D pipeline

Minehart Medical operates three innovation centers with 340+ researchers, engineers, and clinicians.

$214M annual R&D investment
23 active investigational devices
158 peer-reviewed papers (2024)
19 first‑in‑human studies
deep dive into research →

Milton Innovation Campus · BSL‑2/3 labs

Care delivered across 42 countries

Minehart innovations reach over 2,100 hospitals and surgery centers worldwide.

2.4M patients (2024)
380+ clinical sites

Innovation in motion

Recent milestones, publications & regulatory updates.
MAR 12, 2025

Sphere‑9 completes IDE enrollment

Pivotal trial for ventricular tachycardia ablation completes early with 95% enrollment.

Read more →
FEB 28, 2025

New AI model predicts sepsis 6h earlier

Nature Medicine publishes Minehart‑Oxford collaborative study on deep learning.

Read more →
JAN 17, 2025

Acquisition of Nanosensorix

Adding real‑time intraoperative molecular sensing to the innovation portfolio.

Read more →

Let’s advance healthcare together

818-403-5880
contact@minehartcorp.com
16250 Ventura Blvd Ste 165 Encino, CA 91436-22733